中老年人抑郁症状的DNA甲基化特征:多族裔表观基因组-wide研究的荟萃分析
该研究在CHARGE联盟框架下首次跨族裔荟萃分析表观基因组-wide关联研究(EWAS),发现队列包含7948名欧洲裔个体,复制队列包含3308名非洲裔美国人和欧洲裔个体,全血DNA甲基化与抑郁症状关联分析识别出3个显著相关的CpG位点,均指向轴突导向通路,为抑郁的分子机制提供新见解。
要点
- 发现3个与抑郁症状显著相关的甲基化位点:cg04987734、cg12325605和cg14023999。
- 这些位点所在基因或邻近区域提示轴突导向通路可能共同参与抑郁病理。
- CDC42BPB和ARHGEF3的预测表达与重性抑郁相关,支持其功能相关性。
核心结论
- 识别出3个与中老年人抑郁症状相关的全血DNA甲基化位点,均指向轴突导向通路。
研究设计与样本
- 在CHARGE联盟框架下进行跨族裔EWAS荟萃分析,发现队列为7948名欧洲裔个体(来自9个人群队列),复制队列为3308名非洲裔美国人和欧洲裔个体(来自2个人群队列)。
主要发现
- cg04987734(CDC42BPB基因)与抑郁症状增加显著相关(P = 1.57 × 10-08;n = 11 256)。
- cg12325605(ARHGEF3基因)与抑郁症状增加显著相关(P = 5.24 × 10-09;n = 11 256)。
- cg14023999(15q26.1基因间区)与抑郁症状增加显著相关(P = 5.99 × 10-08;n = 11 256)。
- CDC42BPB在脑基底节的预测表达与重性抑郁相关(效应量0.14;P = 2.7 × 10-03)。
- ARHGEF3在成纤维细胞的预测表达与重性抑郁相关(效应量-0.48;P = 9.8 × 10-04)。
临床怎么用
- 目前这些甲基化位点尚不能作为临床生物标志物,需进一步研究验证其效用。
局限性
- 研究仅基于外周血DNA甲基化,不能直接反映脑组织表观遗传状态。
- 复制队列族裔和样本量有限,需更多族裔和更大样本验证。
- 横断面设计无法推断甲基化改变与抑郁症状的因果方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Depressive disorders arise from a combination of genetic and environmental risk factors. Epigenetic disruption provides a plausible mechanism through which gene-environment interactions lead to depression. Large-scale, epigenome-wide studies on depression are missing, hampering the identification of potentially modifiable biomarkers. OBJECTIVE: To identify epigenetic mechanisms underlying depression in middle-aged and elderly persons, using DNA methylation in blood. DESIGN, SETTING, AND PARTICIPANTS: To date, the first cross-ethnic meta-analysis of epigenome-wide association studies (EWAS) within the framework of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium was conducted. The discovery EWAS included 7948 individuals of European origin from 9 population-based cohorts. Participants who were assessed for both depressive symptoms and whole-blood DNA methylation were included in the study. Results of EWAS were pooled using sample-size weighted meta-analysis. Replication of the top epigenetic sites was performed in 3308 individuals of African American and European origin from 2 population-based cohorts. MAIN OUTCOMES AND MEASURES: Whole-blood DNA methylation levels were assayed with Illumina-Infinium Human Methylation 450K BeadChip and depressive symptoms were assessed by questionnaire. RESULTS: The discovery cohorts consisted of 7948 individuals (4104 [51.6%] women) with a mean (SD) age of 65.4 (5.8) years. The replication cohort consisted of 3308 individuals (2456 [74.2%] women) with a mean (SD) age of 60.3 (6.4) years. The EWAS identified methylation of 3 CpG sites to be significantly associated with increased depressive symptoms: cg04987734 (P = 1.57 × 10-08; n = 11 256; CDC42BPB gene), cg12325605 (P = 5.24 × 10-09; n = 11 256; ARHGEF3 gene), and an intergenic CpG site cg14023999 (P = 5.99 × 10-08; n = 11 256; chromosome = 15q26.1). The predicted expression of the CDC42BPB gene in the brain (basal ganglia) (effect, 0.14; P = 2.7 × 10-03) and of ARHGEF3 in fibroblasts (effect, -0.48; P = 9.8 × 10-04) was associated with major depression. CONCLUSIONS AND RELEVANCE: This study identifies 3 methylated sites associated with depressive symptoms. All 3 findings point toward axon guidance as the common disrupted pathway in depression. The findings provide new insights into the molecular mechanisms underlying the complex pathophysiology of depression. Further research is warranted to determine the utility of these findings as biomarkers of depression and evaluate any potential role in the pathophysiology of depression and their downstream clinical effects.
引用
- Story Jovanova O, Nedeljkovic I, Spieler D, et al. DNA Methylation Signatures of Depressive Symptoms in Middle-aged and Elderly Persons: Meta-analysis of Multiethnic Epigenome-wide Studies. JAMA Psychiatry. 2018. PMID: 29998287. doi:10.1001/jamapsychiatry.2018.1725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。